Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia.
The flow cytometric detection of aberrant antigen expression is one method proposed for the quantification of minimal residual disease (MRD) in acute leukemias. The present study was designed to investigate the stability of the aberrant antigen expression at relapse or at treatment failure of initial chemotherapy. For this purpose, multiparameter immunophenotyping with a panel of 15 monoclonal antibodies was used at diagnosis as well as at relapse (43 patients with overall 65 aberrations) and at treatment failure (35 patients with overall 66 aberrations). There was a significant decrease in the percentage of the initially described aberrant antigen expression on leukemia blasts at relapse (P = 0.001; n = 65) as well as at treatment failure (P = 0.0001; n = 66) considering all aberrations in the whole leukemia population. Concerning only patients with acute myelogenous leukemia (AML), significant decreases in the aberrant expression could be detected at relapse (P = 0.031; n = 42) and at treatment failure (P = 0.0001; n = 52). The changes in patients with acute lymphoblastic leukemia (ALL) were significant only at relapse (P = 0.006; n = 23). Initially, the most informative aberration was not detectable in four patients at relapse and in seven patients at treatment failure. A decrease of under 50% of the initial value was observed in another 8 patients at relapse and in 10 patients at treatment failure. In further studies assessing the detection of aberrant antigen expression for MRD, quantification of the relapses should be explicitly analyzed regarding the persistence of the initially described aberrant antigen expression.
Oelschlägel
U
U
Department of Hematology, Medical Clinic and Policlinic I, Technical University Dresden, Dresden, Germany. oelschlaegel@oncocenter.de
Nowak
R
R
Schaub
A
A
Köppel
C
C
Herbst
R
R
Mohr
B
B
Löffler
C
C
Range
U
U
Günther
H
H
Assmann
M
M
Siegert
E
E
Wendt
E
E
Huhn
R
R
Bräutigam
E
E
Ehninger
G
G
D000328:Adult; D015703:Antigens, CD / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000276:immunology / Q000473:pathology; D002648:Child; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D007938:Leukemia / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D012008:Recurrence; D013997:Time Factors; D017211:Treatment Failure
D015703:Antigens, CD; D000970:Antineoplastic Agents